Newcastle disease virus (NDV) recombinants expressing infectious laryngotracheitis virus (ILTV) glycoproteins gB and gD protect chickens against ILTV and NDV challenges

Journal of Virology

Volumn 88, Issue 15, 2014, Pages 8397-8406

  Zhao, Wei ^a   Spatz, Stephen ^a   Zhang, Zhenyu ^a   Wen, Guoyuan ^a   Garcia, Maricarmen ^b   Zsak, Laszlo ^a   Yu, Qingzhong ^a  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRINKING WATER; GLYCOPROTEIN B; GLYCOPROTEIN D; LIVE VACCINE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVIAN INFECTIOUS LARYNGOTRACHEITIS; CHICKEN; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; EMBRYO; ILTOVIRUS; IMMUNIZATION; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; NEWCASTLE DISEASE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE GENETICS; VACCINATION; VIROGENESIS; VIRUS RECOMBINANT; VIRUS TITRATION; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; CHICKENS; GENETIC VECTORS; HERPESVIRIDAE INFECTIONS; NEWCASTLE DISEASE; NEWCASTLE DISEASE VIRUS; POULTRY DISEASES; SEVERITY OF ILLNESS INDEX; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 84903885451     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01321-14     Document Type: Article

References (49)

1. Garcia M, Spatz S, Guy J. 2013. Infectious laryngotracheitis, p 161-179. In Swayne D (ed), Diseases of poultry, vol 13. John Wiley & Sons, Inc., Ames, IA.
2. Gelenczei E, Marty E. 1962. Strain stability and immunologic characterizatics of tissue-culture modified infectious laryngotracheitis virus. Avian Dis. 9:44-56.
3. Samberg Y, Aronovici I. 1969. The devlopment of a vaccine against avian infectious laryngotracheitis. I. Modification of a laryngotracheitis virus. Refu. Vet. 26:54-59.
4. Menendez KR, Garcia M, Spatz S, Tablante NL. 2014. Molecular epidemiology of infectious laryngotracheitis: a review. Avian Pathol. 43:108-117. http://dx.doi.org/10.1080/03079457.2014.886004.
5. Hughes CS, Gaskell RM, Jones RC, Bradbury JM, Jordan FT. 1989. Effects of certain stress factors on the re-excretion of infectious laryngotracheitis virus from latently infected carrier birds. Res. Vet. Sci. 46:274-276.
6. Hughes CS, Williams RA, Gaskell RM, Jordan FT, Bradbury JM, Bennett M, Jones RC. 1991. Latency and reactivation of infectious laryngotracheitis vaccine virus. Arch. Virol. 121:213-218. http://dx.doi.org/10.1007/BF01316755.
7. Guy JS, Barnes HJ, Smith L. 1991. Increased virulence of modified-live infectious laryngotracheitis vaccine virus following bird-to-bird passage. Avian Dis. 35:348-355. http://dx.doi.org/10.2307/1591188.
8. Guy JS, Barnes HJ, Morgan LM. 1990. Virulence of infectious laryngotracheitis viruses: comparison of modified-live vaccine viruses and North Carolina field isolates. Avian Dis. 34:106-113. http://dx.doi.org/10.2307/1591340.
9. Kotiw M, Wilks CR, May JT. 1995. The effect of serial in vivo passage on the expression of virulence and DNA stability of an infectious laryngotracheitis virus strain of low virulence. Vet. Microbiol. 45:71-80. http://dx.doi.org/10.1016/0378-1135(94)00115-D.
10. Barhoom S, Forgacs A, Solyom F. 1986. Development of an inactivated vaccine against laryngotracheitis (ILT)-serological and protection studies. Avian Pathol. 15:213-221. http://dx.doi.org/10.1080/03079458608436282.
11. York JJ, Fahey KJ. 1991. Vaccination with affinity-purified glycoproteins protects chickens against infectious laryngotracheitis herpesvirus. Avian Pathol. 20:693-704. http://dx.doi.org/10.1080/03079459108418808.
12. Johnson DI, Vagnozzi A, Dorea F, Riblet SM, Mundt A, Zavala G, Garcia M. 2010. Protection against infectious laryngotracheitis by in ovo vaccination with commercially available viral vector recombinant vaccines. Avian Dis. 54:1251-1259. http://dx.doi.org/10.1637/9401-052310-Reg.1.
13. Davison S, Gingerich EN, Casavant S, Eckroade RJ. 2006. Evaluation of the efficacy of a live fowlpox-vectored infectious laryngotracheitis/avian encephalomyelitis vaccine against ILT viral challenge. Avian Dis. 50:50-54. http://dx.doi.org/10.1637/7398-062105R.1.
14. Saif YM, Rosenberger J, Cloud S. 1994. Efficacy and safety of a recombinant herpesvirus of turkeys containing genes from infectious laryngotracheitis virus, p 154. In Proceeding of the 130th Annual Meeting of the American Veterinary Medical Association, Minneapolis, MN. American Veterinary Medical Association, Schaumburg, IL.
15. Tong GZ, Zhang SJ, Wang L, Qiu HJ, Wang YF, Wang M. 2001. Protection of chickens from infectious laryngotracheitis with a recombinant fowlpox virus expressing glycoprotein B of infectious laryngotracheitis virus. Avian Pathol. 30:143-148. http://dx.doi.org/10.1080/03079450120044542.
16. Vagnozzi A, Zavala G, Riblet SM, Mundt A, Garcia M. 2012. Protection induced by commercially available live-attenuated and recombinant viral vector vaccines against infectious laryngotracheitis virus in broiler chickens. Avian Pathol. 41:21-31. http://dx.doi.org/10.1080/03079457.2011.631983.
17. Alexander DJ, Senne DA. 2008. Newcastle disease, other avian paramyxoviruses, and pneumovirus infections, p 75-100. In Saif YM, Fadly AM, Glisson JR, McDougald LR, Nolan LK, Swayne DE (ed), Diseases of poultry, 12th ed. Blackwell Publishing, Ames, IA.
18. Hitchner SB. 2004. History of biological control of poultry diseases in the USA. Avian Dis. 48:1-8. http://dx.doi.org/10.1637/6100.
19. Goldhaft TM. 1980. Historical note on the origin of the LaSota strain of Newcastle disease virus. Avian Dis. 24:297-301. http://dx.doi.org/10.2307/1589696.
20. Meulemans G. 1988. Control by vaccination, p 318-332. In Alexander DJ (ed), Newcastle disease. Kluwer Academic Publishers, Boston, MA.
21. Bukreyev A, Collins PL. 2008. Newcastle disease virus as a vaccine vector for humans. Curr. Opin. Mol. Ther. 10:46-55.
22. Huang Z, Elankumaran S, Panda A, Samal SK. 2003. Recombinant Newcastle disease virus as a vaccine vector. Poultry Sci. 82:899-906. http://dx.doi.org/10.1093/ps/82.6.899.
23. Schirrmacher V, Fournier P. 2009. Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol. Biol. 542:565-605. http://dx.doi.org/10.1007/978-1-59745-561-9_30.
24. Vigil A, Martinez O, Chua MA, Garcia-Sastre A. 2008. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol. Ther. 16:1883-1890. http://dx.doi.org/10.1038/mt.2008.181.
25. Zhao H, Peeters BP. 2003. Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication. J. Gen. Virol. 84:781-788. http://dx.doi.org/10.1099/vir.0.18884-0.
26. Hu H, Roth JP, Estevez CN, Zsak L, Liu B, Yu Q. 2011. Generation and evaluation of a recombinant Newcastle disease virus expressing the glycoprotein (G) of avian metapneumovirus subgroupCas a bivalent vaccine in turkeys. Vaccine 29:8624-8633. http://dx.doi.org/10.1016/j.vaccine.2011.09.007.
27. Yu Q, Roth JP, Hu H, Estevez CN, Zhao W, Zsak L. 2013. Protection by recombinant Newcastle disease viruses (NDV) expressing the glycoprotein (G) of avian metapneumovirus (aMPV) subtype A or B against challenge with virulent NDV and aMPV. World J. Vaccines 3:130-139. http://dx.doi.org/10.4236/wjv.2013.34018.
28. Toro H, Zhao W, Breedlove C, Zhang Z, van Santen V, Yu Q. 2014. Infectious bronchitis virus S2 expressed from recombinant virus confers broad protection against challenge. Avian Dis. 58:83-89.
29. Fuchs W, Veits J, Helferich D, Granzow H, Teifke JP, Mettenleiter TC. 2007. Molecular biology of avian infectious laryngotracheitis virus. Vet. Res. 38:261-279. http://dx.doi.org/10.1051/vetres:200657.
30. Connolly SA, Jackson JO, Jardetzky TS, Longnecker R. 2011. Fusing structure and function: a structural view of the herpesvirus entry machinery. Nat. Rev. Microbiol. 9:369-381. http://dx.doi.org/10.1038/nrmicro2548.
31. Spear PG, Longnecker R. 2003. Herpesvirus entry: an update. J. Virol. 77:10179-10185. http://dx.doi.org/10.1128/JVI.77.19.10179-10185.2003.
32. Di Giovine P, Settembre EC, Bhargava AK, Luftig MA, Lou H, Cohen GH, Eisenberg RJ, Krummenacher C, Carfi A. 2011. Structure of herpes simplex virus glycoproteinDbound to the human receptor nectin-1. PLoS Pathog. 7:e1002277. http://dx.doi.org/10.1371/journal.ppat.1002277.
33. Eisenberg RJ, Atanasiu D, Cairns TM, Gallagher JR, Krummenacher C, Cohen GH. 2012. Herpes virus fusion and entry: a story with many characters. Viruses 4:800-832. http://dx.doi.org/10.3390/v4050800.
34. Lazear E, Whitbeck JC, Ponce-de-Leon M, Cairns TM, Willis SH, Zuo Y, Krummenacher C, Cohen GH, Eisenberg RJ. 2012. Antibody-induced conformational changes in herpes simplex virus glycoprotein gD reveal new targets for virus neutralization. J. Virol. 86:1563-1576. http://dx.doi.org/10.1128/JVI.06480-11.
35. Stanberry L. 2013. Pathogens and vaccines: genital and perinatal herpes simplex virus infections, p 273-314. In Stanberry L, Rosenthal S (ed), Sexually-transmitted diseases: vaccines, prevention, and control. Academic Press, London, United Kingdom.
36. Rouse BT, Kaistha SD. 2006. A tale of 2 alpha-herpesviruses: lessons for vaccinologists. Clin. Infect. Dis. 42:810-817. http://dx.doi.org/10.1086/500141.
37. Spatz SJ, Volkening JD, Keeler CL, Kutish GF, Riblet SM, Boettger CM, Clark KF, Zsak L, Afonso CL, Mundt ES, Rock DL, Garcia M. 2012. Comparative full genome analysis of four infectious laryngotracheitis virus (Gallid herpesvirus-1) virulent isolates from the United States. Virus Genes 44:273-285. http://dx.doi.org/10.1007/s11262-011-0696-3.
38. Wyatt LS, Moss B, Rozenblatt S. 1995. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology 210:202-205. http://dx.doi.org/10.1006/viro.1995.1332.
39. Estevez CN, King DJ, Seal B, Yu Q. 2007. Evaluation of Newcastle disease virus chimeras expressing the hemagglutinin-neuraminidase protein of velogenic strains in the context of a mesogenic recombinant virus backbone. Virus Res. 129:182-190. http://dx.doi.org/10.1016/j.virusres.2007.07.008.
40. Alexander DJ. 1998. Newcastle disease virus and other avian paramyxoviruses, p 156-163. In Swayne D, Glisson JR, Jackwood MW, Pearson JE, ReedWM(ed), A laboratory manual for the isolation and identification of avian pathogens, 4th ed. American Association of Avian Pathologists, Kennett Square, PA.
41. Kapczynski DR, King DJ. 2005. Protection of chickens against overt clinical disease and determination of viral shedding following vaccination with commercially available Newcastle disease virus vaccines upon challenge with highly virulent virus from the California 2002 exotic Newcastle disease outbreak. Vaccine 23:3424-3433. http://dx.doi.org/10.1016/j.vaccine.2005.01.140.
42. Callison SA, Riblet SM, Oldoni I, Sun S, Zavala G, Williams S, Resurreccion RS, Spackman E, Garcia M. 2007. Development and validation of a real-time Taqman PCR assay for the detection and quantitation of infectious laryngotracheitis virus in poultry. J. Virol. Methods 139:31-38. http://dx.doi.org/10.1016/j.jviromet.2006.09.001.
43. Vagnozzi A, Riblet SM, Zavala G, Garcia M. 2012. Optimization of a duplex real-time PCR method for relative quantitation of infectious laryngotracheitis virus. Avian Dis. 56:406-410. http://dx.doi.org/10.1637/9883-081111-ResNote.1.
44. Kolakofsky D, Roux L, Garcin D, Ruigrok RW. 2005. Paramyxovirus mRNA editing, the "rule of six" and error catastrophe: a hypothesis. J. Gen. Virol. 86:1869-1877. http://dx.doi.org/10.1099/vir.0.80986-0.
45. Nakaya T, Cros J, Park MS, Nakaya Y, Zheng H, Sagrera A, Villar E, Garcia-Sastre A, Palese P. 2001. Recombinant Newcastle disease virus as a vaccine vector. J. Virol. 75:11868-11873. http://dx.doi.org/10.1128/JVI.75.23.11868-11873.2001.
46. Guy JS, Bagust TJ. 2003. Laryngotracheitis, p 121-134. In Saif YM, Barnes HJ, Glisson JR, Fadly AM, McDougald LR, Swayne DE (ed), Diseases of poultry, 11th ed. Iowa State Press, Ames, IA.
47. Mebatsion T, Nelson L, Hein R. 2008. XXIII World Poultry Conference, p 42-44. World Poultry Science Association, Brisbane, Australia.
48. Kapczynski DR, Afonso CL, Miller PJ. 2013. Immune responses of poultry to Newcastle disease virus. Dev. Comp. Immunol. 41:447-453. http://dx.doi.org/10.1016/j.dci.2013.04.012.
49. Rodriguez-Avila A, Oldoni I, Riblet S, Garcia M. 2007. Replication and transmission of live attenuated infectious laryngotracheitis virus (ILTV) vaccines. Avian Dis. 51:905-911. http://dx.doi.org/10.1637/8011-041907-REGR.1.